Genmab A/S (NASDAQ:GMAB) Shares Gap Down – Time to Sell?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares gapped down prior to trading on Friday . The stock had previously closed at $27.06, but opened at $25.56. Genmab A/S shares last traded at $26.0260, with a volume of 2,212,462 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Guggenheim decreased their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Jefferies Financial Group assumed coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective for the company. Finally, HC Wainwright decreased their price objective on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $39.07.

Genmab A/S Stock Down 3.4%

The firm has a market cap of $16.29 billion, a P/E ratio of 16.83, a P/E/G ratio of 1.24 and a beta of 0.86. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The firm’s fifty day moving average is $27.32 and its 200 day moving average is $29.91.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.41). The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. As a group, equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.19 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC raised its stake in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. raised its stake in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in Genmab A/S in the 1st quarter worth about $34,000. NewEdge Advisors LLC raised its stake in Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. raised its stake in Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.